Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen

Autor: Kok, M, Linn, SC, Van Laar, RK, Jansen, Maurice, Berg, Tineke, Delahaye, LJMJ, Glas, AM, Peterse, JL, Hauptmann, M (Michael), Foekens, John, Klijn, Jan, Wessels, LFA, van 't Veer, LJ (Laura), Berns, Els

Publikováno v: Breast Cancer Research and Treatment, 113(2), 275-283. Springer New York

Background Molecular signatures that predict outcome in tamoxifen treated breast cancer patients have been identified. For the first time, we compared these response profiles in an independent cohort of (neo)adjuvant systemic treatment na < ve breast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::dcc09e25184965270984e767010e1f94
https://pure.eur.nl/en/publications/e8548bc4-3996-4db1-85b5-d8ffaa7ceb9d

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology.

Autor: Mittempergher L; Research and Development, Agendia NV, Amsterdam, the Netherlands., Delahaye LJMJ; Research and Development, Agendia NV, Amsterdam, the Netherlands., Witteveen AT; Research and Development, Agendia NV, Amsterdam, the Netherlands., Spangler JB; Product Support, Agendia Inc., Irvine, California., Hassenmahomed F; Research and Development, Agendia NV, Amsterdam, the Netherlands., Mee S; Product Support, Agendia Inc., Irvine, California., Mahmoudi S; Research and Development, Agendia NV, Amsterdam, the Netherlands., Chen J; Product Support, Agendia Inc., Irvine, California., Bao S; Product Support, Agendia Inc., Irvine, California., Snel MHJ; Research and Development, Agendia NV, Amsterdam, the Netherlands., Leidelmeijer S; Research and Development, Agendia NV, Amsterdam, the Netherlands., Besseling N; Research and Development, Agendia NV, Amsterdam, the Netherlands., Bergstrom Lucas A; Diagnostics and Genomics Group, Agilent Technologies, Santa Clara, California., Pabón-Peña C; Diagnostics and Genomics Group, Agilent Technologies, Santa Clara, California., Linn SC; Division of Molecular Pathology and Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Dreezen C; Research and Development, Agendia NV, Amsterdam, the Netherlands., Wehkamp D; Research and Development, Agendia NV, Amsterdam, the Netherlands., Chan BY; Product Support, Agendia Inc., Irvine, California., Bernards R; Research and Development, Agendia NV, Amsterdam, the Netherlands; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands., van 't Veer LJ; Research and Development, Agendia NV, Amsterdam, the Netherlands; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California., Glas AM; Research and Development, Agendia NV, Amsterdam, the Netherlands. Electronic address: annuska.glas@agendia.com.

Publikováno v: The Journal of molecular diagnostics : JMD [J Mol Diagn] 2019 Sep; Vol. 21 (5), pp. 808-823. Date of Electronic Publication: 2019 Jun 04.

A breast cancer gene signature for indolent disease.

Autor: Delahaye LJMJ; Agendia NV, Science Park 406, 1098 XH, Amsterdam, The Netherlands., Drukker CA; Department of Surgical Oncology and Division of Molecular Carcinogenesis, Netherlands Cancer Institute, PO Box 90203, 1006 BE, Amsterdam, The Netherlands.; Department of Surgery, Academic Medical Center, University of Amsterdam, PO Box 22660, 1100 DD, Amsterdam, The Netherlands., Dreezen C; Agendia NV, Science Park 406, 1098 XH, Amsterdam, The Netherlands., Witteveen A; Agendia NV, Science Park 406, 1098 XH, Amsterdam, The Netherlands., Chan B; Agendia Inc, 22 Morgan, Irvine, CA, 92618, USA., Snel M; Agendia NV, Science Park 406, 1098 XH, Amsterdam, The Netherlands., Beumer IJ; Agendia NV, Science Park 406, 1098 XH, Amsterdam, The Netherlands., Bernards R; Agendia NV, Science Park 406, 1098 XH, Amsterdam, The Netherlands.; Department of Surgical Oncology and Division of Molecular Carcinogenesis, Netherlands Cancer Institute, PO Box 90203, 1006 BE, Amsterdam, The Netherlands., Audeh MW; Agendia Inc, 22 Morgan, Irvine, CA, 92618, USA., Van't Veer LJ; Agendia NV, Science Park 406, 1098 XH, Amsterdam, The Netherlands. laura.vantveer@ucsf.edu.; Department of Laboratory Medicine, UCSF Helen Diller Family Comprehensive Cancer Centre, 2340 Sutter Street, San Francisco, CA, 94115, USA. laura.vantveer@ucsf.edu., Glas AM; Agendia NV, Science Park 406, 1098 XH, Amsterdam, The Netherlands. annuska.glas@agendia.com.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2017 Jul; Vol. 164 (2), pp. 461-466. Date of Electronic Publication: 2017 Apr 27.